Evaluate Rituximab in Obtaining PCR (Polymerase Chain Reaction) Negative Leukapheresis Product in Patients With Relapsed Follicular Lymphoma

• Status: Completed
• Trial end date: 2015-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Researchers hope to learn if adding rituximab with high doses of chemotherapy and stem cell transplantation will help patients get rid of their lymphoma cells from the bone marrow and stem cell collections.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Kansas; University of Kansas Medical Center
• Treatments: Rituximab

Criteria

Inclusion Criteria:

• Patients with biopsy-proven refractory CD20+ (cluster of differentiation antigen 20) Follicular lymphoma or transplant eligible mantle cell lymphoma in CR1 (complete remission 1) or later.

• Patients must be transplant eligible per KUCC BMT SOP (Kansas University Cancer Center Bone Marrow Transplant Standard Operation Procedures) with chemo-sensitive/marrow negative disease.

• Patients planning to harvest and hold may also be included as long as above criteria are met.

Exclusion Criteria:

• Pregnancy

• Zubrod performance status greater than 2

• Life expectancy is severely limited by concomitant illness.

• Uncontrolled arrhythmias or symptomatic cardiac disease precluding transplantation

• Symptomatic pulmonary disease precluding transplantation

• Serum creatinine greater than 1.8 mg/dL

• Serum bilirubin greater than 2 X upper limit of normal, SGPT (serum glutamate pyruvate transaminase) greater than 3 times upper limit of normal

• Evidence of chronic active hepatitis or cirrhosis

• Unable to sign informed consent.

• Allergy to Rituximab